Standing up in public for a broader conception of value in healthcare.

41-48 of 60 News

viewpoint 2/02/17

On the Health Affairs Blog: Neumann Discusses Cures Act and New FDA Draft Guidance on Communication Provisions of the 21st Century Cures Act and new FDA draft guidance suggest greater flexibility for drug companies in the communication of the real-world drug impacts of their products. READ MORE

viewpoint 1/19/17

Peter Neumann in New England Journal of Medicine: Cost-Effectiveness 2.0 -- Poised for a Second Act? IVI's Peter Neumann offers a new perspective on cost-effectiveness analysis in the New England Journal of Medicine. READ MORE

viewpoint 12/29/16

On the Health Affairs Blog: Germany's Drug Price Model-- Would It Work in the US? Karl Lauterbach, John McDonough, and Elizabeth Seeley suggest that Germany's AMNOG model should be applied to US drug pricing policy. READ MORE

viewpoint 12/27/16

On the Health Affairs Blog: The Demise of the Part B Demo Rachel Dolan examines the uproar over specific Medicare Part B policies supporting value-based payment. READ MORE

viewpoint 12/09/16

Jason Shafrin Discusses Value-Based Pricing on The Washington Post's In Theory Blog Jason Shafrin examines the complexities of drug pricing and advocates for value-based pricing structures in an op-ed for The Washington Post's In Theory blog, titled "How we should pay for cures, according to economics,". READ MORE

viewpoint 12/01/16

Philipson in Forbes: Assessing Healthcare Value Needs A Decentralized Approach In Tomas Philipson's latest op-ed, he provides a step-by-step breakdown of the steps necessary for creating a new, decentralized and scientific approach to value-based pricing and reimbursement. READ MORE

viewpoint 11/30/16

On the Health Affairs Blog: 21st Century Cures Legislation A Bad Deal for Patients Ameet Sarpatwari and Michael Sinha discuss why the current 21st Century Cures legislation increases risk of patient harm, and adds pressure on the FDA to rush new products to market without adequate evidence. READ MORE

viewpoint 11/21/16

On the Health Affairs Blog: Divorcing Reimbursement From Real-World Prices David Tawes and Marta Wosinska examine why Medicare still uses 2003 AWPs for some drugs, and suggest a path forward. READ MORE